Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 3 | 5 |
| 2005 | 4 | 1 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Screening for Prostate Cancer. N Engl J Med. 2023 Jul 06; 389(1):93-94.
-
Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. Ann Intern Med. 2022 11; 175(11):1582-1590.
-
Changing Provider PSA Screening Behavior Using Best Practice Advisories: Interventional Study in a Multispecialty Group Practice. J Gen Intern Med. 2020 11; 35(Suppl 2):796-801.
-
Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice. J Gen Intern Med. 2020 05; 35(5):1368-1374.
-
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6721-6730.
-
Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. Perm J. 2019; 23.
-
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 05 08; 319(18):1901-1913.
-
The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. JAMA. 2017 May 16; 317(19):1949-1950.
-
Prostate cancer in black men: Is it time for personalized screening approaches? Cancer. 2017 06 15; 123(12):2203-2205.
-
Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. BJU Int. 2017 10; 120(4):520-529.